Skip to main content
. Author manuscript; available in PMC: 2012 Feb 1.
Published in final edited form as: Inflamm Bowel Dis. 2011 Feb;17(2):503–515. doi: 10.1002/ibd.21391

Figure 4.

Figure 4

(A) Chemotaxis of untreated, calcein-stained neutrophils against recombinant MIP-2 (5–20 ng/mL) without or with 25 or 50 μM curcumin in the lower chamber of the ChemoTx® Chemotaxis System. * p≤0.05 MIP-2 vs. control; # p≤0.05 curcumin vs. control or curcumin/MIP-2 vs. MIP-2 alone. (B) Chemotaxis of neutrophils pretreated with 10–50μM of curcumin (30 min prior to the assay) against recombinant MIP-2 (20ng/mL) * p≤0.05 MIP-2 vs. control; # p≤0.05 Curcumin 10μM/MIP-2 vs. MIP-2 alone; † Curcumin 25 or 50μM vs. Curcumin 10μM/MIP-2 or MIP-2 alone. (C) Chemokinesis assay of PMN with recombinant MIP-2 (20ng/mL) placed in the top and bottom chamber. PMNs were pretreated with curcumin (10, 25 or 50μM) 30 minutes prior to the assay. * p≤0.05 10–25μM curcumin vs. DMSO; # p≤0.05 50 μM curcumin vs. control or 10–20 μM curcumin (ANOVA followed by Fisher PLSD post-hoc test). (D) Chemotaxis of untreated, calcein-stained neutrophils against recombinant KC (75 ng/mL) without or with 25 or 50 μM curcumin in the lower chamber of the ChemoTx® Chemotaxis System. * p≤0.05 KC vs. control; # p≤0.05 KC/curcumin vs. KC; ** control vs. curcumin alone.